Literature DB >> 3905992

Comparative trial of co-trimoxazole versus tetracycline-streptomycin in treating human brucellosis.

J Ariza, F Gudiol, R Pallarés, G Rufí, P Fernández-Viladrich.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3905992     DOI： 10.1093/infdis/152.6.1358

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  11 in total

Review 1.  Cotrimoxazole. Rationale for re-examining its indications for use.

Authors:  R A Howe; R C Spencer
Journal:  Drug Saf       Date:  1996-04       Impact factor: 5.606

2.  Bilateral mammary abscess and uveitis caused by Brucella melitensis--report of a case.

Authors:  I Gasser; B Almirante; F Fernández-Pérez; C Mendoza
Journal:  Infection       Date:  1991 Jan-Feb       Impact factor: 3.553

Review 3.  The current therapeutical strategies in human brucellosis.

Authors:  Mile Bosilkovski; Fariba Keramat; Jurica Arapović
Journal:  Infection       Date:  2021-03-01       Impact factor: 3.553

4.  Treatment of human brucellosis with doxycycline and gentamicin.

Authors:  J Solera; A Espinosa; E Martínez-Alfaro; L Sánchez; P Geijo; E Navarro; J Escribano; J A Fernández
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

5.  Comparative in vitro activities of ofloxacin, difloxacin, ciprofloxacin, and other selected antimicrobial agents against Brucella melitensis.

Authors:  M Y Khan; M Dizon; F W Kiel
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

Review 6.  Recognition and optimum treatment of brucellosis.

Authors:  J Solera; E Martínez-Alfaro; A Espinosa
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

7.  In vitro susceptibility of Brucella melitensis to antibiotics.

Authors:  E Rubinstein; R Lang; B Shasha; B Hagar; L Diamanstein; G Joseph; M Anderson; K Harrison
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

8.  Relevance of in vitro antimicrobial susceptibility of Brucella melitensis to relapse rate in human brucellosis.

Authors:  J Ariza; J Bosch; F Gudiol; J Liñares; P F Viladrich; R Martín
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

9.  Doxycycline-rifampin versus doxycycline-streptomycin in treatment of human brucellosis due to Brucella melitensis. The GECMEI Group. Grupo de Estudio de Castilla-la Mancha de Enfermedades Infecciosas.

Authors:  J Solera; M Rodríguez-Zapata; P Geijo; J Largo; J Paulino; L Sáez; E Martínez-Alfaro; L Sánchez; M A Sepulveda; M D Ruiz-Ribó
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

Review 10.  Systematic review and meta-analysis of randomized clinical trials in the treatment of human brucellosis.

Authors:  Julián Solís García del Pozo; Javier Solera
Journal:  PLoS One       Date:  2012-02-29       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.